Shortlist Revealed For 2024 GGB Awards

Finalists Named With Winners To Be Announced At 9 October Ceremony In Milan

The final shortlist of entries across all 14 categories of the Global Generics & Biosimilars Awards 2024 has now been revealed, ahead of our prizegiving ceremony in Milan on 9 October.

Shortlist letters on board
Our shortlist of finalists has now been published • Source: Shutterstock

The final shortlist of entries has now been published for the Global Generics & Biosimilars Awards 2024, ahead of the winners being revealed at our ceremony in Milan on 9 October. Click here to see the full details.

Covering activities undertaken between 1 September 2023 and 31 July 2024, the entries have been evaluated by our panel of independent expert judges to compile the shortlist of finalists. A prizegiving ceremony announcing the winners will then take place at the Hotel NH Milano Fiera on Wednesday 9 October, during CPhI Worldwide week.

Dave Wallace, executive editor of Generics Bulletin, said “We’re delighted to announce such a high-quality shortlist for the Global Generics and Biosimilars Awards 2024, reflecting the ongoing contributions made by the off-patent pharmaceutical industry worldwide.”

“This year saw the usual large number of excellent entries covering numerous impressive achievements, and our judging panel has had a very difficult job in narrowing them down to these select finalists. I’d like to thank the judges for volunteering their time and expertise, as well as all those companies that entered. Congratulations to all of this year’s finalists, and we look forward to celebrating the winners in a month’s time in Milan.”

Podcast: The Global Generics & Biosimilars Awards 2024
In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.
Discover the full story

For more details on the event, Generics Bulletin’s editors recorded a podcast talking about the benefits of attending the awards – which remains free of charge – as well as exploring the reasons why off-patent industry players might want to be involved with the event (see sidebar).

Backed by our headline sponsor IQVIA, category sponsors for the awards also include Adalvo in the Active Pharmaceutical Ingredient supplier of the Year category, Aurobindo for Industry Partner of the Year, Cerba Research for Company of the Year – Americas, as well as Pharmacloud for our Leader of the Year category.

The awards are also supported by International Health Partners in our corporate social responsibility initiative of the year category. Our 2024 supporters also include the International Generic and Biosimilars Medicines Association, as well as the US Association for Accessible Medicines and its Biosimilars Council.

Other categories will include our company of the year award and our two other regional company of the year awards for the Asia-Pacific and EMEA regions; acquisition of the year; biosimilar initiative of the year; and business development of the year.

Meanwhile, further awards will recognize the best campaign of the year; regulatory achievement of the year; and value added medicine initiative of the year.

For a full list of the awards categories, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail Christopher.keeling@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2024, to receive the latest updates and for any further details, please e-mail Natalia.kay@citeline.com

More from Generics

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By 

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By 

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”